Ebola surges past 3,200 cases in DRC as Oxford begins first vaccine trial

Health workers take precautionary measures The death toll from an Ebola outbreak in DRC has climbed to 1,405, with confirmed cases now at 3,200, government data showed Sunday as researchers race to develop a vaccine Kinshasa, DRC | AGENCIES | Medics have recorded more than 3,200 Ebola cases, including over 1,400 deaths, in the Democratic Republic of Congo’s 17th outbreak, officials said on July 26 after infections surged by around 1,000 in just 10 days. The central African nation is battling its latest Ebola epidemic in the conflict-ridden east, a region scarred by decades of violence. Cases have now been confirmed across five provinces, official figures showed, after the outbreak passed the 2,000-case mark on 15 July.

Authorities said improved detection and testing had helped identify more infections. In Uganda, all 20 cases so far have been diagnosed in Kampala, with no community spread reported. The country reported two deaths, with the last Ebola patient leaving hospital on July 16.

Uganda’s last reported case, confirmed on June 21, was related to travel from DRC. The outbreak, declared on 15 May, is caused by the Bundibugyo strain of the Ebola virus, for which there is no approved vaccine or treatment. Nearly 90 per cent of cases have been reported in the northeastern province of Ituri, which borders South Sudan and Uganda, according to the World Health Organization (WHO).

The outbreak could last several more months, while strikes by healthcare workers demanding unpaid wages have disrupted response efforts in some hospitals. Ebola spreads through contact with bodily fluids and causes haemorrhagic fever. It has killed more than 15,000 people across Africa over the past 50 years.

Scientists are racing to develop vaccines and treatments against the Bundibugyo strain. Oxford University said on Friday that the first volunteer group had received an experimental vaccine specifically targeting the virus. Dr David Pulido-Gomez, Global Chemistry, Manufacturing and Controls (CMC) lead, Pandemic Sciences Institute, Nuffield Department of Medicine, said that “reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort.

Working alongside colleagues at the CBF and SII, we’ve taken this vaccine candidate from concept to clinic in just eight weeks.” Several other candidate vaccines are being fast-tracked for clinical trials, while t…